<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05796089</url>
  </required_header>
  <id_info>
    <org_study_id>TROG 20.01 CHEST RT</org_study_id>
    <nct_id>NCT05796089</nct_id>
  </id_info>
  <brief_title>TROG 20.01 CHEST RT: Chemotherapy and Immunotherapy in Extensive Stage Small Cell Lung Cancer With Thoracic Radiotherapy</brief_title>
  <official_title>A Phase II Study of Platinum and Etoposide Chemotherapy, Durvalumab With Thoracic Radiotherapy in the First Line Treatment of Patients With Extensive-stage Small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trans Tasman Radiation Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Trans Tasman Radiation Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy and Immunotherapy in extensive stage small cell lung cancer with thoracic&#xD;
      radiotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase II study of platinum and etoposide chemotherapy, durvalumab with thoracic&#xD;
      radiotherapy in the first line treatment of patients with extensive-stage small-cell lung&#xD;
      cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2022</start_date>
  <completion_date type="Anticipated">July 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm open label prospective multicentre Phase II trial No control group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety change</measure>
    <time_frame>At 4 weeks, 12 weeks, 24 weeks, 36 weeks, 52 weeks, 68 weeks, 88 weeks, 104 weeks, 124 weeks, 140 weeks, 140 weeks, 156 weeks</time_frame>
    <description>Safety assessed according to the Common Terminology Criteria for Adverse Events (CTCAE5) for oesophageal or pneumonitis toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of treatment change</measure>
    <time_frame>At 4 weeks, 8 weeks, 24 weeks, 36 weeks, 52 weeks, 68 weeks, 88 weeks, 104 weeks, 124 weeks, 140weeks and 156 weeks post completion of chemo-immunotherapy.</time_frame>
    <description>Feasibility assessed by the continuation of systematic therapy is considered safe secondary to radiation toxicities (as assessed by a clinical assessment by a clinician) and the ability of the disease to be encompassed within a reasonable radiation portal and completing the full course of radiation therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Death due to any cause as time to event and proportion at one year and 2 years post intervention commencement</time_frame>
    <description>Overall survival assessed at follow up visits or via medical records of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Death or disease progression as time to event and proportion at 6 months and 1 year post-intervention commencement</time_frame>
    <description>Progression free survival assessed at follow up visits or via medical records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of failure</measure>
    <time_frame>Patterns of failure detected at imaging at cycle 2/day 11 of chemo-immunotherapy then at 4 weeks, 8 weeks, 24 weeks, 36 weeks, 52week, 68 weeks, 88 weeks, 104 weeks, 124 weeks, 140weeks and 156 weeks post completion of chemo-immunotherapy.</time_frame>
    <description>Patterns of failure assessed by the proportion of patients with first site of failure in: Thoracic, Extra-thoracic or cranial sites, seen on imaging (CT/MRI) and assessed by iRECIST and/or RANO-BM criteria. (The first site of treatment relapse will be collected and categorised as thoracic, extra-thoracic or cranial).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Extensive-stage Small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>30Gy in 10 fractions. Radiation therapy (RT) to be given either concurrently with cycle 3 or 4 of chemotherapy or within 6 weeks of finishing chemotherapy. Fractions are expected to be delivered daily. All RT treatment should be completed within 15 days</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Durvalumab:&#xD;
Dose - 1500mg | To be administered by intravenous infusion with chemotherapy every 3 weeks for 4 cycles. Once the chemotherapy cycles complete, 1500mg of Durvalumab will be given every 4 weeks until disease progression (also known as maintenance therapy).&#xD;
Etoposide:&#xD;
Dose - as standard practice | Treatment with chemotherapy will be limited to 4 cycles on a 3 weekly schedule. It is to be prescribed and administered by intravenous infusion according to local prescribing information.&#xD;
Platinum based chemotherapy (Cisplatin or Carboplatin):&#xD;
Dose - as standard practice | Treatment with chemotherapy will be limited to 4 cycles on a 3 weekly schedule. It is to be prescribed and administered by intravenous infusion according to local prescribing information.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than or equal to 18,&#xD;
&#xD;
          -  Untreated ES-SCLC patients&#xD;
&#xD;
          -  Provided written informed consent&#xD;
&#xD;
          -  Histologically or cytologically documented ES-SCLC - ES-SCLC defined as; American&#xD;
             Joint Committee on Cancer [8th edition] SCLC stage IV&#xD;
&#xD;
               -  T any, N any, M1 a/b/c, or&#xD;
&#xD;
               -  T3?4 due to multiple lung nodules that are too extensive or have tumour/nodal&#xD;
                  volume that is too large to be encompassed in a feasible radiation plan&#xD;
&#xD;
          -  ECOG performance-status score of 0 or 1 at registration. Patients with worse&#xD;
             performance status (PS) prior to cycle 1 may be included if PS improves to 0-1 prior&#xD;
             to cycle 2; these patients would be registered prior to cycle 2&#xD;
&#xD;
          -  Life expectancy greater than or equal to 12 weeks at registration&#xD;
&#xD;
          -  Brain metastases must be controlled or asymptomatic&#xD;
&#xD;
          -  Thoracic disease deemed suitable for radiation therapy following initial systemic&#xD;
             therapy&#xD;
&#xD;
          -  Bodyweight of at least 30 kg&#xD;
&#xD;
          -  Suitability for first-line platinum-based chemotherapy&#xD;
&#xD;
          -  Adequate organ and marrow function; and negative pregnancy test for pre-menopausal&#xD;
             women&#xD;
&#xD;
          -  No prior exposure to immune-mediated therapy including, but not limited to, other&#xD;
             anti-cytotoxic T-lymphocyte-associated antigen-4, anti-programmed cell death-1,&#xD;
             anti-programmed cell death ligand-1, and anti-programmed cell death ligand-2&#xD;
             antibodies, excluding therapeutic anticancer vaccines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous high dose radiotherapy to the chest precluding mediastinal radiation&#xD;
&#xD;
          -  Significant active or previous autoimmune or inflammatory disorder&#xD;
&#xD;
          -  Paraneoplastic syndrome of autoimmune nature requiring systemic treatment&#xD;
&#xD;
          -  Interstitial lung disease/pulmonary fibrosis&#xD;
&#xD;
          -  History of active primary immunodeficiency&#xD;
&#xD;
          -  Uncontrolled, concurrent illness or active infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Hau</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westmead/Blacktown Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bridget Rooney</last_name>
    <phone>+61 2 40143911</phone>
    <email>CHESTRT@trog.com.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Hau</last_name>
    <phone>+61 2 9881 8421</phone>
    <email>eric.hau@health.nsw.gov.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Hau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Hau</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LiverpoolHospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalini Vinod</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Bettington</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margot Lehman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Parkville</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Harnden</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Mitchell</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>February 9, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

